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Flurbiprofen belongs to Biopharmaceutical Classification System (BCS) class II drugs which are 
poorly soluble in water. The objective of present research work was to prepare fast dissolving tablets of 
Flurbiprofen using varying concentrations of three different sublimating agents to improve the dissolution 
rate. Seven formulations were prepared containing different concentrations of camphor, ammonium 
bicarbonate and thymol as sublimating agent along with primogel as a superdisintegrant. Tablets were 
manufactured by direct compression method. The prepared tablets were evaluated for pre-compression 
and post-compression parameters result, For all formulations result was within official limits. FTIR 
studies revealed that there were no interactions between the drug and the excipients used. From in vitro 
drug release studies it was concluded that the formulations F6 and F7 containing 10% and 15% of thymol 
showed fast drug release of 100.00% and 100.84% respectively in 30 minutes. Formulations containing 
camphor (F2 & F3) and ammonium bicarbonate (F4 & F5) as sublimating agents showed a drug release 
of less than 80%, while the control formulation F1 having no sublimating agent showed 49.14% of 
drug release in 30 minutes. Thus thymol can successfully be used to formulate fast dissolving tablets of 
flurbiprofen by sublimation method with much better dissolution profile. 
Keywords: Flurbiprofen/dissolution. Fast dissolving tablets. Drug release. Sublimating agent. 
Superdisintegrant.
INTRODUCTION
Most appropriate route for drug administration is 
oral route because of versatility, simplicity of intake and 
most importantly patient compliance. Fast dissolving 
tablets are acquiring eminence as modern system of drug 
delivery because disintegration time of such formulations 
is within seconds to minutes (El-Enin, 2014). Fast 
dissolving tablets are very beneficial in administration of 
drugs to children; bedridden patients, in patients having 
dysphagia, stroke, thyroid disorder, Parkinson’s diseases 
and multiple sclerosis, patients with nausea, vomiting 
and motion sickness leading to improved patient 
compliance (Kuchekar, Badhan, Mahajan, 2003).Rate of 
drug dissolution can be enhanced by different methods 
which include Direct compression, Wet granulation, 
Molding, Spray drying, Freeze drying, Lyophilisation 
and Sublimation (Mettu, Veerareddy, 2013; Nagar et 
al., 2011).
The main objective of preparation of Fast Dissolving 
Tablets (FDT’s) is to prepare a porous matrix of tablets. 
In sublimation technique for the preparation of such a 
porous structure various highly volatile ingredients like 
ammonium bicarbonate, ammonium carbonate, benzoic 
acid, camphor, naphthalene, urea, urethane, thymol and 
phthalic anhydride etc are incorporated in the formulation. 
Different solvents can also be used for formation of porous 
matrix, these solvents include cyclohexane, benzene and 
many others (Goel et al., 2008). In this study sublimation 
technique was employed for designing seven formulations 
of Flurbiprofen FDT’s by use of varying proportions 
of camphor, ammonium bicarbonate and thymol as 
sublimating agents.
MATERIAL AND METHODS
Flurbiprofen, thymol, camphor, ammonium 
bicarbonate were received as a gift from Medizan 
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Laboratories and all the other ingredients used were of 
analytical grade. 
Manufacturing of the tablets
Seven formulations (F1, F2, F3, F4, F5, F6 and 
F7) of Flurbiprofen (FLB) tablets were designed in such 
a way that F1 was control containing no sublimating 
agent. Formulation F2 and F3 contained 10% and 15% 
of camphor respectively as sublimating agent, F4 and 
F5 contained 10% and 15% of ammonium bicarbonate, 
while F6 and F7 contained 10% and 15% of thymol as 
sublimating agent.
Accurately weighed quantity of each excipient was 
mixed except magnesium stearate and talcum and passed 
through sieve #60. After sufficient mixing accurately 
weighed quantity of magnesium stearate and talcum 
were added for lubrication (Vemula, Neduri, 2015). The 
compositions of the formulations are presented in Table I.
After this, powder mixture of each formulation was 
evaluated for angle of repose, bulk density, tapped density. 
The fixed funnel method was employed to measure 
the angle of repose (θ) and it was calculated using the 
following formula:
Tan θ = h/r
where, θ is angle of repose, h is height of the cone, and r 
is radius of the cone base. 
Powder was mixed properly and approximately 2 g 
of finely mixed powder was added in a funnel which was 
then set in such a way that lower tip of funnel slightly 
touches the peak of powder heap. Funnel was set on 
plane surface and powder was passed freely through it. 
Measurement of diameter was then done and calculations 
were done according to above equation (Neduri, Bontha, 
Vemula, 2013). Bulk density was measured by taking 2 g 
of properly mixed powder of each formulation into 10 mL 
of graduated measuring cylinder and powder volume was 
observed (Neduri, Bontha, Vemula, 2013). For measuring 
tapped density cylinder was tapped on a hard surface 
after every 2 seconds and this procedure was repeated 
until no change in volume was observed. Final volume 
of powder was then measured. The compressibility index 
was determined from the bulk and tapped densities and 
was calculated using the following formula:
Compressibility index= (Tapped Density-Bulk density)/
Tapped Density x 100
After pre-compression studies the powder blend 
of each formulation was compressed using compression 
machine ZP 17 with punch size of 12 mm. Finally the 
prepared tablets (except F1) were heated in a hot air oven 
at 60 °C for 2 hours for removing sublimating agent until 
constant weight of tablet was achieved.
Post-compression parameters of the tablets
The prepared tablets were studied for post 
compression parameters like weight variation, hardness 
and friability. For estimating weight variation, 20 tablets 
of each formulation were weighed using an analytical 
weighing balance (Shimadzu, UX 420H). The strength of 
tablet is expressed by measuring hardness and friability. 
The hardness of six tablets was measured using Monsanto 
tablet hardness tester. Friability of ten tablets was 
determined using Roche friabilator for 4 min at 25 rpm.
Disintegration time
It was calculated by the use of USP disintegration 
test apparatus. This apparatus consists of a basket rack 
containing 6-open-ended glass tubes held in a vertical 
position. A number 10-mesh stainless steel wire screen 
is attached to the bottom. To test for disintegration time, 
one tablet from each formulation was individually added 
into the basket of disintegration apparatus and temperature 
was set at 37+ 2 °C. Finally time required for complete 
disintegration was recorded (Kumar et al., 2009).
Wetting time and water absorption ratio
One tablet selected from each formulation was 
placed in a Petri plate with internal diameter of 10 cm, 
having circular tissue paper folded twice. 0.5% (w/v) of 
phenol red was added in 10mL of water and this solution 
was then poured into petri plate and after complete wetting, 
time was noted using stop watch. For determination of 
water absorption ratio same test was conducted without 
using phenol red. Calculation of Water absorption ratio 
(R) was done according to formula given below (Vemula, 
Reddy, 2015).
R = Wa-Wb/Wb×100
Wa represent weight of tablet after wetting, while Wb 
represent weight of tablet before wetting.
Dispersion time
From each formulation one tablet was selected 
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randomLy and time in which the tablet gets dispersed 
entirely was noted. For this purpose 10 mL of water was 
added in a glass beaker and tablet was added into it. Finally 
dispersion time was observed and noted using stop watch. 
The results were recorded in triplicates (Jadhav et al., 2011).
Analysis of drug content
For preparation of sample solution 10 tablets from 
each formulation were randomLy selected and crushed 
into fine powder by using pestle and mortar. This fine 
powder blend equivalent to 100 mg of flurbiprofen was 
then added in 100 mL of 0.1N NaOH and sonicated for 
30 minutes. After filtration determination of drug content 
was done with UV spectrophotometer at 247 nm (Javed 
et al., 2013).
In vitro dissolution study
Flurbiprofin dissolution study was carried out using 
dissolution type II apparatus. This test was conducted 
for 45 minutes in 900 mL of 0.1 N HCl at 37±0.5 °C and 
50 rpm. In vitro release was determined by collecting 
5 mL of sample after 0, 5, 10, 15, 20, 25, 30, 35, 40, 45 
minutes and replacing with fresh media. These samples 
were analysed by UV-visible spectrophotometer at 247nm 
(Valleri et al., 2004).
Kinetics of drug release
For determination of kinetics of drug release for each 
formulation of FDTs, Zero-order, First-order, Higuchi’s, 
Hixson & Crowell and Korsemeyer Peppas equations were 
applied on data (Neau et al., 1999; Makhija, Vavia, 2002).
Statistical analysis of data
For determination of significant difference in drug 
release kinetics of different formulations statistical tests 
including ANOVA and t-test were applied.
Fourier transform infrared spectroscopy (FTIR)
Infrared spectroscopy of pure FLB, active ingredient 
plus excipients blend of all the formulations was carried 
out using FTIR spectrophotometer. The spectra were 
scanned over a frequency range of 3500 to 1000 cm-1 
(Mettu, Veerareddy, 2013).
Stability studies
For assessment of stability of active and final 
formulations, ICH guidelines were followed and stability 
studies were carried out accordingly. All the samples were 
carefully packed in aluminium foil and kept in humidity 
chamber set at temperature and humidity conditions of 
40±2 °C and 75±5% RH respectively for one month 
(Vemula, Neduri, 2015). 
RESULTS AND DISCUSSION
Pre-compression parameters
Each formulation blend of drug and excipients 
TABLE I - Composition of formulations prepared by sublimation technique
Excipients (mg/tab)
Formulations
F1 F2 F3 F4 F5 F6 F7
Flurbiprofen 100 100 100 100 100 100 100
Microcrystalline cellulose(102) 243 198 175.5 198 175.5 198 175.5
Lactose SD 35 35 35 35 35 35 35
Primogel 20 20 20 20 20 20 20
Colloidal silicon dioxide 4 4 4 4 4 4 4
Thymol - - - - - 45 67.5
Camphor - 45 67.5 - - - -
Ammonium bicarbonate - - - 45 67.5 - -
Mannitol 30 30 30 30 30 30 30
Talcum 8 8 8 8 8 8 8
Magnesium stearate 10 10 10 10 10 10 10
Net weight 450 450 450 450 450 450 450
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prepared were evaluated for angle of repose, bulk density, 
tapped density and compressibility index. Bulk density 
was found in the range of 0.35-0.45 g/mL and tapped 
density between 0.39-0.50 g/mL. Angle of repose was 
also evaluated which was between 24.36 and 30.50. The 
powder blends of all the formulations had compressibility 
index between 10.01 and 13.32 as shown in Table II. The 
results indicated that the powder blends possessed ideal 
properties required to be produced by direct compression 
method.
Post-compression parameters
Flurbiprofen fast dissolving tablets were prepared 
in seven formulations (F1 was control having no 
sublimating agent) by compressing powder blend using 
direct compression technique.The data obtained from 
post-compression parameters such as thickness, hardness, 
friability, weight variation, amount of drug content, 
wetting time, water absorption ratio and disintegration 
time are shown in Table III.
Tablet hardness values lied between 5.0 ± 0.21 to 
5.4 ± 0.33 kg/cm2(acceptance range = 5-8 kg/cm2) for 
all the formulations indicating good mechanical strength 
with an ability to withstand physical and mechanical stress 
conditions while handling. Thickness value of tablets lied 
between 3.20 ± 0.05 to 3.24 ± 0.06 mm (acceptance range 
= ± 5%).In all the formulations the friability values were 
less than 1% and met the Pharmacopoeial limits. The loss 
of percentage of weight of all the formulations in friability 
was 0.41 ± 0.02 to0.58 ± 0.06 which was well below the 
allowed official limits.
Wetting time of tablets prepared from sublimation 
technique ranged from 51 ± 0.49 to 56 ± 0.85 seconds. 
Dispersion time values were found in the range from 54 
± 0.24 to 61 ±0.47 seconds. Results of disintegration test 
lied between 40 ± 0.79 to 46 ± 0.25 seconds (acceptable 
disintegration time standards are 5 minutes).The results 
TABLE II - Pre-compression parameters of the formulations
Formulations
Bulk Density 
(g/mL) ± S.D 
(n=3)
Tapped Density 
(g/mL) ± S.D 
(n=3)
Hausner’s 
Ratio ± S.D 
(n=3)
Angle of 
Repose ± S.D 
(n=3)
Compressibility 
Index (%) ± S.D 
(n=3)
F 1 0.43 ± 0.025 0.49 ± 0.042 1.12 ± 0.037 26.66 ± 0.73 11.51 ± 0.76
F 2 0.36 ± 0.033 0.42 ± 0.074 1.14 ± 0.038 25.10 ± 0.71 13.32 ± 0.79
F 3 0.35 ± 0.033 0.39 ± 0.012 1.10 ± 0.031 24.36 ± 0.68 10.01 ± 0.42
F 4 0.45 ± 0.041 0.51 ± 0.017 1.18 ± 0.046 25.24 ± 0.70 12.85 ± 0.62
F 5 0.37 ± 0.022 0.42 ± 0.074 1.15 ± 0.039 30.31 ±0.60 11.08 ± 0.42
F 6 0.45 ±0.041 0.51 ± 0.017 1.15 ± 0.039 29.89 ± 0.61 12.87 ± 0.68
F7 0.45 ± 0.041 0.50 ± 0.017 1.10 ± 0.031 30.50 ± 0.60 10.94 ± 0.43
TABLE III - Post compression parameters of the formulations
Sr. Parameters F 1 F 2 F 3 F 4 F 5 F6 F7
1 Hardness (kg/cm
2) ± 
SD, n=3
5.4 ± 0.33 5.2 ± 0.29 5.0 ± 0.21 5.1 ± 0.14 5.0 ± 0.20 5.1 ± 0.14 5.0 ± 0.24
2 Thickness (mm) ± 
SD, n=3
3.21 ±0.04 3.23 ± 0.03 3.23 ± 0.05 3.20 ± 0.09 3.20 ± 0.05 3.24 ± 0.06 3.21 ± 0.09
3 Friability (%w/w) ± 
SD, n=3
0.58 ± 0.06 0.41± 0.04 0.43 ± 0.08 0.41± 0.02 0.48 ± 0.04 0.43 ± 0.02 0.51 ± 0.09
4 Disintegration Time 
(Sec) ± SD, n=3 
46 ± 0.25 43 ± 0.21 45 ± 0.49 43 ± 0.57 45 ± 0.40 40 ± 0.79 41 ± 0.73
5 Wetting Time (Sec) ± 
SD, n=3 
56 ± 0.85 55 ± 0.11 56 ± 0.14 54 ± 0.36 51 ± 0.49 56 ± 0.50 54± 0.32
6 Dispersion Time (Sec) 
± SD, n=3
54 ± 0.55 58 ± 0.91 54 ± 0.45 61 ± 0.21 60 ± 0.26 61 ± 0.47 54 ± 0.24
7 Drug Content 100.03% 99.97% 100.03% 99.99% 99.98% 99.99% 100.02%
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of wetting time and disintegration time of all the tablets 
were found to be within the prescribed limits and satisfied 
the criteria of fast dissolving tablets. All the formulations 
possessed acceptable hardness, friability, wetting time and 
disintegration time which is an absolute requirement for 
any fast dissolving tablet.
From the dissolution studies, cumulative percentage 
of drug release versus time was evaluated as presented in 
Figure 1. Figure 1 represents the percentage release of 
all the formulations against time. It also reflects that the 
formulations F6 and F7 containing 45 mg and 67.5 mg of 
thymol respectively showed fast drug release of 100.00% 
and 100.84% respectively in 30 minutes as compared 
with formulations containing other sublimating agents. 
Among all the formulations, F6 and F7 tablets showed 
complete drug release within 30 minutes and rapid 
dissolution. The possible reasons and mechanisms for 
increased dissolution rates are formation of porous 
structure on the surface of tablet due to sublimation and 
the presence of superdisintegrants which enhance the 
water permeation (wicking action) into the tablet, which 
leads to a prompt wetting action, short disintegration 
time and finally causes the fast dissolution rate. It 
was observed that as the concentration of sublimating 
agents was increased the drug release also increased, 
because as the concentration of sublimating agent 
increases, there will be more number of pores formed 
in the tablet, because of which water can enter and get 
absorbed in more quantity, which will lead to rapid 
disintegration.
Drug release rates obtained for the formulations 
were subjected for kinetic treatment to know the order 
of drug release rates. Values of the drug release were 
attempted to fit into various mathematical models to 
observe the mechanism as showed in Table IV. The 
correlation coefficient values were obtained for all the five 
models. Model fitting plots of the optimized formulations 
best suited Krosmeyers-Peppas release kinetics as shown 
in Figure 2- Figure 6.
FIGURE 1 - Drug release (%) of formulations versus time (min).
FIGURE 2 - Zero order release kinetics plot. 
FIGURE 3 - First order release kinetics plot.
TABLE IV - Drug release kinetics (R2 values of formulations)
Formulations F1 F2 F3 F4 F5 F6 F7
Zero order 0.8824 0.8125 0.5329 0.5900 0.5053 0.0225 -0.5311
First order 0.9176 0.9403 0.9707 0.9582 0.9451 0.9474 0.9156
Higuchi plots 0.8594 0.9556 0.9857 0.9869 0.9893 0.8883 0.8095
Hixon and Crowell 0.9180 0.9388 0.9375 0.9216 0.9034 0.9666 0.9719
Korsemeyer peppas plots 0.9328 0.9834 0.9858 0.9882 0.9893 0.9159 0.9741
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ANOVA results are shown in Table V. If F value is 
greater than Fcritvalue it shows significant difference in 
drug release profile of different formulations. According 
to results presented in Table V. F>Fcrit F value 3.4814 is 
greater than Fcrit value 2.2655. Therefore results confirm 
that there is significant difference in drug release of the 
seven formulations. 
t-Test was also performed and results revealed that 
t Stat < t Critical two-tail it means that there is significant 
difference between the drug release kinetics of the 
optimized formulations prepared by sublimation technique 
and the control formulation.
The FT-IR studies revealed that flurbiprofen is 
compatible with the excipients used in the formulation. 
There were no extra peaks observed in the IR spectrum. 
The IR absorption band in cm
-1 
of the drug and excipients 
FIGURE 4 - Higuchi model plot.
FIGURE 5 Hixon-Crowell model plot.
FIGURE 6 - Krosmeyers-Peppas model plot.
TABLE V - Results of one way ANOVA
Anova: Single Factor
SUMMARY
Groups Count Sum Average Variance
Row 1 9 406.64 45.18222 418.9677
Row 2 9 528.34 58.70444 469.3118
Row 3 9 613.41 68.15667 476.8833
Row 4 9 579.31 64.36778 438.8329
Row 5 9 613.19 68.13222 449.5777
Row 6 9 736.6 81.84444 545.937
Row 7 9 759.27 84.36333 445.0354
ANOVA
Source of Variation SS Df MS F P-value F crit
Between Groups 9682.063987 6 1613.677 3.481455 0.005388 2.265567
Within Groups 25956.36691 56 463.5066
Total 35638.4309 62    
For the determination of difference of the drug 
release between the control formulation and the other 
six formulations t-test and ANOVA were applied 
on data.
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was found to be similar. This established that the drug 
flurbiprofen and all the excipients used in the study showed 
no interaction and indicated that they were compatible 
with each other.
FTIR spectrum of pure FLB show the characteristic 
peaks shown below: (Sohail et al., 2014)
Visual representation of FTIR spectra of active 
and powder mixture of best formulations presented in 
Figure 7- Figure 9.
Stability studies were carried out on optimized 
formulations F6 and F7. Formulations were stored at 40oC 
± 2 °C /75 ± 5% RH for 30 days. No significant changes 
were found during study period. Thus the formulations 
were found to be stable.
CONCLUSION
In conclusion, FDTs of Flurbiprofen were developed 
that had sufficient mechanical integrity, and uniformity of 
content. The FDTs were prepared by direct compression 
method using sublimation technique. All tablets had 
hardness in the range 5.0–5.4 kg/cm2 and friability 
less than 1%. Weight variation and drug content of 
all formulations were within official limits. In vitro 
disintegration tests and in vitro drug release studies of 
FDTs tablets showed that best formulations F6 and F7 
containing 10% and 15% of Thymol as sublimating agent 
disintegrate within seconds and the total amount of drug 
was released within 30 minutes while none of the other 
formulations showed complete release of the drug within 
specified time. Hence, the optimized formulations F6 
and F7 can be effectively used for the treatment of pain, 
arthritis and other inflammatory conditions.
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FIGURE 8 - FTIR spectra of formulation F6.
FIGURE 9 - FTIR spectra of formulation F7.
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